Key result
Lp(a) measurement faces persistent inaccuracies from apo(a) size heterogeneity and inconsistent assay calibration.
Answers are grounded in this paper and cite their sources.
Accurate measurement of Lipoprotein(a) remains challenging but is vitally important given new guidelines recommending universal testing and emerging targeted therapies.
Lipoprotein(a) [Lp(a)] is a causal, independent risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis. New guidelines recommend testing everyone at least once in a lifetime, and with new drugs specifically targeting Lp(a) on the horizon, accurate measurement remains vitally important. Yet, its measurement has for decades been challenging because of apolipoprotein(a) size heterogeneity, imperfect calibration strategies, and mixed use of mass (mg/dL) vs. molar (nmol/L) units. This review summarizes Lp(a) biology relevant to its measurement, current analytical approaches and their pitfalls, progress toward standardization and harmonization, including emerging mass-spectrometry–based reference measurement procedures.
No takes yet. Share an insight, caveat, or question.
John H. Contois (2026) conducted a review in Atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Lipoprotein(a) measurement was evaluated. Lipoprotein(a) measurement remains challenging due to apolipoprotein(a) size heterogeneity, imperfect calibration strategies, and mixed use of mass versus molar units.
Synapse has enriched 10 related papers. Consider them for comparative context: